Dromers Monday, 07/27/20 11:17:06 AM Re: None Post # of 543 Health Canada Approves Cannabis Research License for EnWave’s Canadian Headquarters VANCOUVER, British Columbia, July 27, 2020 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that the Company has obtained a Research License from Health Canada under the Cannabis Act for its Vancouver-based facilities (the “License”). With a pilot plant that is now approved for independent research and development for cannabis products, EnWave has the ability to expedite process development and data analytics for terpene and cannabinoid retention along with other critical properties of cannabis. This strategy is designed to further demonstrate the significant value proposition of the Company’s proprietary, vacuum-microwave drying technology. Previous trials conducted at our licensed partners’ facilities yielded very positive results. With a Health Canada License, this valuable in-house research can further facilitate adoption decisions by Canadian and international cannabis producers looking to up-scale their post-harvest drying operations. It also allows EnWave to better advance the research process, working independently and in collaboration with cannabis companies at its on-site facilities. Through its new licensed capabilities, EnWave is intensifying its efforts to support licensed producers looking to improve their drying processes. EnWave’s proprietary Radiant Energy Vacuum (“REV™”) drying technology provides cannabis producers with a rapid drying solution that creates high quality cannabis products for both extraction and combustion, while reducing processing bottlenecks at lower operating costs. The REV™ process also significantly reduces the bioburden in the product and reduces crop loss due to microbes and other quality issues. REV™ has already been adopted by several licensed cannabis and hemp producers in Canada, Switzerland, New Zealand, Australia and the United States of America. With EnWave conducting on-site trials with a variety of cannabis strains, the perceived technology risk is anticipated to be materially reduced for prospective licensees and is targeted to stimulate new licenses and REV™ equipment sales into the sector.